Clinical Trials Logo

Clinical Trial Summary

This multicenter, randomized study will evaluate the efficacy and safety of apatinib compared to docetaxel treatment in patients with advanced gastric cancer. At the start of the trial, patients will be randomized to one treatment arm: Arm A: apatinib 850mg qd every 3 weeks; Arm B: docetaxel 60mg/m2 every 3 weeks. Tumor assessment will be done every 8 weeks according to RECIST 1.1. The primary endpoint is progression free survival (PFS).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02409199
Study type Interventional
Source Shanghai Zhongshan Hospital
Contact Liu Tianshu, doctor
Phone +862152303355
Email liu.tianshu@zs-hospital.sh.cn
Status Recruiting
Phase Phase 2/Phase 3
Start date June 2015
Completion date March 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Not yet recruiting NCT03599778 - XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma Phase 1/Phase 2
Terminated NCT00256321 - Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma Phase 2
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Recruiting NCT02617134 - CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor Phase 1/Phase 2
Recruiting NCT02317471 - Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96 Phase 1/Phase 2
Active, not recruiting NCT03735511 - A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
Recruiting NCT04410302 - Patient-Derived Xenografts to Reduce Cancer Health Disparities
Recruiting NCT05596188 - Anxiety Before Non-cardiac Surgery in Adults
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Terminated NCT04254107 - A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Phase 1
Recruiting NCT01348009 - Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer Phase 1/Phase 2
Recruiting NCT00639522 - Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma Phase 1
Recruiting NCT05811546 - Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma
Recruiting NCT05229809 - Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer Phase 4
Completed NCT00970138 - Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer Phase 2/Phase 3
Recruiting NCT06408220 - Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer N/A
Recruiting NCT04443036 - Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma N/A
Active, not recruiting NCT04505553 - Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer Phase 2
Recruiting NCT02839954 - CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor Phase 1/Phase 2